Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-09-11
1994-02-01
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
424 9, 540145, A61K 3140
Patent
active
052832554
ABSTRACT:
A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
REFERENCES:
patent: 4649151 (1987-03-01), Dougherty et al.
patent: 4883790 (1989-11-01), Levy et al.
Chow Jack J.
Dolphin David
Levy Julia G.
Sternberg Ethan
Raymond Richard L.
The University of British Columbia
LandOfFree
Wavelength-specific cytotoxic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Wavelength-specific cytotoxic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Wavelength-specific cytotoxic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-580055